A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.

Launched by HOFFMANN-LA ROCHE · Jun 27, 2007

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • post-menopausal women with osteoporosis;
• • \<=80 years of age;
• • naive to oral bisphosphonates, or have discontinued daily and/or weekly bisphosphonate treatment for \>1 year.
• Exclusion Criteria:
• • metabolic bone disease other than post-menopausal osteoporosis;
• • treatment with other drugs affecting bone metabolism within last 6 months;
• • previous or current malignant disease (except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer).

Trial Officials